Skip to main content
. 2022 Nov 7;12:877635. doi: 10.3389/fonc.2022.877635

Figure 2.

Figure 2

Increased human T cells in spleens and TILs of HIS-CRC-BRGS mice treated with combination cabozantinib and nivolumab. The HIS in LNs, spleens and tumors from HIS-CRC-BRGS mice were analyzed by flow cytometry for human immune subset frequencies (%) and cell numbers per g of tumor: (A) overall human (hCD45+) as a percentage of total immune cells (human + mouse CD45+), (B) T cells (CD3+), (C) CD4 and CD8+ T cells, (D) CD19+ B cells and (E) human myeloid cells as determined by markers CD11b, CD11c, CD14 or CD33. Right panel is frequency of myeloid cells with low HLA-DR class II expression. V=untreated, N=nivolumab alone, Ca=cabozantinib alone and Ca/N=combination cabozantinib and nivolumab. P-values indicate ANOVA multiple comparisons with Welch’s correction: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or as indicated by number.